Compare LII & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LII | INCY |
|---|---|---|
| Founded | 1895 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8B | 17.0B |
| IPO Year | 1999 | 1994 |
| Metric | LII | INCY |
|---|---|---|
| Price | $507.85 | $96.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 20 |
| Target Price | ★ $569.45 | $104.05 |
| AVG Volume (30 Days) | 386.1K | ★ 1.3M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | 1.11 | ★ 4173.33 |
| EPS | ★ 22.79 | 6.41 |
| Revenue | ★ $5,195,300,000.00 | $3,394,635,000.00 |
| Revenue This Year | $6.90 | $10.48 |
| Revenue Next Year | $5.73 | $10.99 |
| P/E Ratio | $21.50 | ★ $15.13 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $434.06 | $56.16 |
| 52 Week High | $689.44 | $112.29 |
| Indicator | LII | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 53.10 |
| Support Level | $481.66 | $93.54 |
| Resistance Level | $532.29 | $108.79 |
| Average True Range (ATR) | 17.46 | 2.45 |
| MACD | 6.49 | 0.80 |
| Stochastic Oscillator | 97.76 | 81.39 |
Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounted for 67% of sales and commercial HVAC (building climate solutions) accounted for the remaining 33% of sales. To be clear, Lennox's commercial exposure is what its peers refer to as "residential and light commercial," lacks the scale and complexity of what is referred to as an "applied" solution. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.